Intravitreal Bevacizumab for Diabetic Macular Edema
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
Kiungo kimehifadhiwa kwenye clipboard
Hali
Wadhamini
Isfahan Ophthalmology Research Center
JARIBIO LA KLINIKI: NCT00703235
BioSeek: nct00703235
Maneno muhimu
Kikemikali
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.
This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
Tarehe
| Imethibitishwa Mwisho: | 05/31/2008 |
| Iliyowasilishwa Kwanza: | 06/19/2008 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 06/19/2008 |
| Iliyotumwa Kwanza: | 06/22/2008 |
| Sasisho la Mwisho Liliwasilishwa: | 06/19/2008 |
| Sasisho la Mwisho Lilichapishwa: | 06/22/2008 |
Hali au ugonjwa
Macular Edema
Diabetic Retinopathy
Uingiliaji / matibabu
Drug: Bevacizumab
Awamu
Awamu 2/Awamu 3
Vigezo vya Kustahiki
| Jinsia Inastahiki Kujifunza | All |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - Diabetes mellitus - Clinically significant macular edema - Possibility of performing macular OCT - Consent of patient for inclusion in the study Exclusion Criteria: - History of macular photocoagulation in less than 6 months of inclusion in the study - Necessity of surgical intervention - Rejection of the remaining in the study by patient |
